Loading
Corvel Corp Stock: price and insider trades · United States
Corvel Corp: what insiders have been doing
This page follows insider dealings at Corvel Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Irvine. The group dates from 1988. Over the twelve months to 20 October 2026, 61 filings were filed, from 16 insiders.
No insider bought on the market over the period, while 7 insiders filed 22 sales totalling €17.2M. The largest single trade was a sale of €7.7M by Corstar Holdings Inc, published on 15 September 2026, equal to 0.23% of the market capitalisation.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For context, the typical company on the same exchange (median of 5,453 companies) published 22 filings over the same period, against 61 filings here. Our records for Corvel Corp go back to 2016, with no purchases and 702 sales on the open market in total. For the fiscal year to 31 March 2026, the annual 10-K puts revenue at 958.5 m USD and net income at 110.3 m USD.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
1,160
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€155M
702 ops. · all time
Who traded when
BuySaleMichael G. Combs8 sales
R. Judd Jessup8 sales
Alan Hoops6 sales
Corstar Holdings Inc6 sales
Clemons V Gordon4 sales
Jennifer Yoss4 sales
+5 other insiders
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 10,482 of 26,272 companies
56.7
score / 100
Value40
Quality73
FCF yld2.7%
Earn yld2.7%
EV/EBITDA23.2x
ROE31%
Gross mgn24%
Net mgn12%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
US$79.72
Analyst consensus
Income statement
RevenueUS$958.5M
Gross profitUS$232.9M24% margin
EBITDAUS$174.9M18% margin
Net incomeUS$110.3M11.7% margin
Valuation
PER (trailing)35.6x
P/Book9.9x
Beta1.05
Balance sheet & cash
Market capUS$4B
Total debtUS$28.1M
Free Cash FlowUS$110.3M
Debt / Equity7%
Profitability & ownership
ROE30.7%
ROA14.7%
% insiders38.9%
% institutions56.1%
Last declaration on 1 October 2026
Declarations1,160 total
45 shares@ US$70.82250.0001% mcap0.0% of flowCommon StockSEC:0001641248-26-000018:0
36 shares@ US$70.82250.0001% mcap0.1% of flowCommon StockSEC:0001754632-26-000011:0
9 shares@ US$70.82250.0000% mcap0.1% of flowCommon StockSEC:0001921051-26-000014:0
55 shares@ US$70.82250.0001% mcap42.3% of flowCommon StockSEC:0002100449-26-000006:0
30,925 shares@ US$69.04780.056% mcap3.4% of flowCommon StockSEC:0001256520-26-000004:0
127,824 shares@ US$70.15940.23% mcap14.5% of flowCommon StockSEC:0001256520-26-000004:1
127,824 shares@ US$70.2030.23% mcap14.5% of flowCommonSEC144:0001969223-26-001021
29,556 shares@ US$69.04920.053% mcap3.3% of flowCommonSEC144:0001969223-26-001016
30,925 shares@ US$69.06470.056% mcap3.4% of flowCommonSEC144:0001969223-26-001019
51,713 shares@ US$68.91120.093% mcap5.8% of flowCommon StockSEC:0001256520-26-000002:0
14,538 shares@ US$68.75590.026% mcap1.6% of flowCommon StockSEC:0001256520-26-000002:1
14,538 shares@ US$68.530.026% mcap1.6% of flowCommonSEC144:0001969223-26-000998
51,713 shares@ US$68.87540.093% mcap5.7% of flowCommonSEC144:0001969223-26-000995
4,023 shares@ US$70.070.0074% mcap5.5% of flowCommon StockSEC:0001204612-26-000008:0
1,562 shares@ US$70.710.0029% mcap2.2% of flowCommon StockSEC:0001204612-26-000006:0
1,262 shares@ US$70.640.0023% mcap1.7% of flowCommon StockSEC:0001204612-26-000006:1
6,847 shares@ US$71.04990.013% mcap9.5% of flowCommonSEC144:0001959173-26-006396
2,100 shares@ US$65.720.0036% mcap7.2% of flowCommon StockSEC:0001754632-26-000009:0
2,100 shares@ US$70.9150.0039% mcap7.7% of flowCommon StockSEC:0001754632-26-000009:1
2,100 shares@ US$70.9150.0039% mcap100.0% of flowCommonSEC144:0001950047-26-008495
51 shares@ US$52.6470.0001% mcap49.7% of flowCommon StockSEC:0002100449-26-000004:0
45 shares@ US$59.100.0001% mcap49.2% of flowCommon StockSEC:0002100449-26-000004:1
1 shares@ US$59.100.0000% mcap1.1% of flowCommon StockSEC:0002100449-26-000004:2
9,000 shares@ US$14.440.0034% mcap2.9% of flowCommon StockSEC:0001230877-26-000002:0
634 shares@ US$62.250.0011% mcap6.4% of flowCommon StockSEC:0001921051-26-000012:1
25 of 1160 declarations
About Corvel Corp
CorVel Corp. (ticker: CRVL) is a U.S.-based healthcare services and claims-management company listed on the NASDAQ in the United States. For French-speaking investors in France, Belgium, or Switzerland, CorVel is best understood as a specialized provider of medical cost containment and claims administration solutions, with a business model built around workflow automation, data-driven decision support, and integrated service delivery. The company was founded in 1987 under the name FORTIS by V. Gordon Clemons and went public in 1991. Its headquarters are in Irvine, California, and it serves more than 1,000 clients, including employers, insurance carriers, and government entities.([corvel.com](https://www.corvel.com/company/investors/?utm_source=openai))
CorVel’s core offering is an integrated platform covering claims management, case management, medical bill review, provider network management (PPO), pharmacy-related solutions, disability management, and liability/auto claims services. The company primarily addresses workers’ compensation, liability, disability, and alternative risk programs. A key differentiator is its proprietary technology stack, including CareMC®, which helps customers manage claims files, trigger alerts, track exceptions, and improve visibility across the claims lifecycle. CorVel also emphasizes its AI-based rules engine, used to support medical review, compliance, and anomaly detection across large volumes of claims and billing data.([sec.gov](https://www.sec.gov/Archives/edgar/data/874866/000095017025076999/crvl-20250331.htm))
Read moreShow less
From a competitive standpoint, CorVel occupies a niche position. The company describes itself as the only independent publicly traded claims management and cost containment provider, which gives it a distinct profile versus broader healthcare services or insurance technology peers. Its competitive edge comes from combining software-enabled automation with outsourced operational services, allowing customers to reduce administrative burden and medical spend while improving processing speed and compliance. That model tends to support recurring revenue relationships and embeds the company deeply into customer workflows.([corvel.com](https://www.corvel.com/company/investors/?utm_source=openai))
CorVel’s geographic footprint is primarily domestic, focused on the United States, where it serves customers across multiple regions through a national service and provider network. Because its solutions are tied to state-level workers’ compensation rules, billing practices, and claims processes, regulatory expertise is an important part of its market positioning.([sec.gov](https://www.sec.gov/Archives/edgar/data/874866/000095017025076999/crvl-20250331.htm))
Recent developments point to a constructive operating trajectory. For the fiscal year ended March 31, 2025, CorVel reported revenue of $896 million, up from $795 million in the prior year, and highlighted continued investment in AI to enhance communications, bill review, and fraud/waste/abuse detection. The company also ended the period with no borrowings, underscoring a conservative balance-sheet profile. For investors, CorVel remains a profitable, technology-enabled healthcare services company with defensive end markets and a clear specialization in claims cost containment in the United States.([corvel.com](https://www.corvel.com/insights/corvel-announces-fiscal-year-revenues-and-earnings-fy-2025/?utm_source=openai))
